Sign in
CompletedPhase 1/2

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

Key facts

Who runs it
ModernaTX, Inc.
Where
East Greenwich, Hollywood, Lenexa, Lincoln, Savannah, South Jordan, Southfield, Sugar Land, and Tomball, United StatesSee the 9 sitesAlso in 1 other country, 18 sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
1,504 people enrolled
Started
10 Jul 2023
Ended
16 Jul 2024
Type of study
Interventional, 15 groups
Treatments tested
  • mRNA-1018 for H5N8
  • mRNA-1018 for H7N9
  • mRNA-1018 for H5 Only
  • mRNA-1018 for H7 Only
  • mRNA-1018 for H5 Only-CG
Record updated
16 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and results of electrocardiogram testing
  • Body mass index of 18 kilograms (kg)/square meter (m\^2) to 39 kg/m\^2 (inclusive) at the Screening visit
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception, and not currently breastfeeding

Who cannot take part

  • Participant is acutely ill or febrile (body temperature ≥ 38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1
  • Participant has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 180 days prior to Screening Visit (for corticosteroids ≥10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study
  • Participant has received any vaccine authorized or approved by local health agency including mRNA vaccine ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after the study intervention
  • Participant has participated in an interventional clinical study within 28 days prior to the Screening visit based on the medical history interview or plans to do so while participating in this study; Other inclusion/exclusion criteria may apply
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures
  • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results

Where in United States

Also in 1 other country, 18 sites

  • Velocity Clinical Research, ProvidenceEast Greenwich, United States
  • CenExel RCAHollywood, United States
  • Johnson County Clin-TrialsLenexa, United States
  • Velocity Clinical ResearchLincoln, United States
  • Velocity Clinical ResearchSavannah, United States
  • J. Lewis Research, Inc/Jordan River Family MedicineSouth Jordan, United States
  • DM Clinical ResearchSouthfield, United States
  • DM Clinical ResearchSugar Land, United States
  • DM Clinical ResearchTomball, United States

About the trial

What the trial wants to find out

The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).

The 15 groups in the trial

  • Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 1Treatment being tested

    Participants will receive mRNA-1018 for H5N8 at dose level 1 by intramuscular (IM) injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5N8

  • Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 2Treatment being tested

    Participants will receive mRNA-1018 for H5N8 at dose level 2 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5N8

  • Part A Group 1 Vaccine: mRNA-1018 for H5N8 Dose Level 3Treatment being tested

    Participants will receive mRNA-1018 for H5N8 at dose level 3 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5N8

  • Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 1Treatment being tested

    Participants will receive mRNA-1018 for H5 only at dose level 1 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5 Only

  • Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 2Treatment being tested

    Participants will receive mRNA-1018 for H5 only at dose level 2 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5 Only

  • Part A Group 1 Vaccine: mRNA-1018 for H5 Only Dose Level 3Treatment being tested

    Participants will receive mRNA-1018 for H5 only at dose level 3 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5 Only

  • Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 1Treatment being tested

    Participants will receive mRNA-1018 for H7N9 at dose level 1 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H7N9

  • Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 2Treatment being tested

    Participants will receive mRNA-1018 for H7N9 at dose level 2 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H7N9

  • Part A Group 2 Vaccine: mRNA-1018 for H7N9 Dose Level 3Treatment being tested

    Participants will receive mRNA-1018 for H7N9 at dose level 3 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H7N9

  • Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 1Treatment being tested

    Participants will receive mRNA-1018 for H7 only at dose level 1 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H7 Only

  • Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 2Treatment being tested

    Participants will receive mRNA-1018 for H7 only at dose level 2 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H7 Only

  • Part A Group 2 Vaccine: mRNA-1018 for H7 Only Dose Level 3Treatment being tested

    Participants will receive mRNA-1018 for H7 only at dose level 3 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H7 Only

  • Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 1Treatment being tested

    Participants will receive mRNA-1018 for H5 Only-CG at dose level 1 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5 Only-CG

  • Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 2Treatment being tested

    Participants will receive mRNA-1018 for H5 Only-CG at dose level 2 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5 Only-CG

  • Part B Group 1 Vaccine: mRNA-1018 for H5 Only-CG Dose Level 3Treatment being tested

    Participants will receive mRNA-1018 for H5 Only-CG at dose level 3 by IM injection on Day 1 and Day 22.

    Treatment: mRNA-1018 for H5 Only-CG

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2, Randomized, Observer-Blind, Parallel, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults ≥18 Years of Age
Publications
Record updated
16 July 2025